The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).
 
Dong-Wan Kim
No Relationships to Disclose
 
Marcello Tiseo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Otsuka; Pierre Fabre
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
Research Funding - AstraZeneca
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; Boehringer Ingelheim
Research Funding - Adaptimmune; ARIAD; Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis; Pfizer; Pfizer; Xcovery
 
Karin Holmskov Hansen
Honoraria - Novartis
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer
 
Sang-We Kim
No Relationships to Disclose
 
Rudolf M. Huber
Honoraria - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Novartis; Roche
Research Funding - Pierre Fabre
 
Howard Jack West
Honoraria - Celgene; Foundation Medicine; Genentech/Roche; Merck; Novartis; Pfizer
Consulting or Advisory Role - Celgene; Foundation Medicine; Genentech/Roche; Merck; Novartis; Pfizer
Travel, Accommodations, Expenses - Celgene; Foundation Medicine; Genentech/Roche; Merck; Novartis; Novartis
 
Harry J.M. Groen
Consulting or Advisory Role - Lilly (Inst); MSD (Inst); Roche (Inst)
 
Maximilian J. Hochmair
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
 
Scott N. Gettinger
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen
Research Funding - ARIAD (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Pfizer (Inst)
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer/Onyx; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck; Millennium
Research Funding - Advantagene (Inst); Ariad (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst)
 
Luis G. Paz-Ares
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Pfizer; Roche/Genentech
 
Egbert F. Smit
Consulting or Advisory Role - Lilly
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Roche/Genentech (Inst)
 
Edward S. Kim
Honoraria - AstraZeneca; Celgene; Lilly
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Lilly; Myriad Genetics
Research Funding - Celgene; Lilly
 
William G Reichmann
No Relationships to Disclose
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Frank G. Haluska
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD